Nitin Gupta, MD
Gastroenterology · Atlanta, GANPI 1013113364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $950,834 of the $1,071,300 with a category attached, or 88.8%. 36 manufacturers reported payments, led by AbbVie at 48.0% of the total. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,162 payments — averaging $921.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$514K
- Johnson & Johnson$217K
- Janssen Scientific Affairs, LLC$125K
- E.r. Squibb & Sons, L.L.C.$111K
- Lilly USA, LLC$52K
- Pfizer$47K
- plus $4K from 30 others
Across 162 payments — averaging $3605.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$286K
- Roche Products Limited$96K
- Genentech, Inc.$88K
- Pfizer$44K
- E.r. Squibb & Sons, L.L.C.$31K
- Amgen$27K
- plus $12K from 3 others
What the payments were for
- Consulting fees$4,2000%
- Speaking & faculty fees$950,83489%
- Travel & lodging$92,7039%
- Food & beverage$23,0472%
- Education$5150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 515 | $514,017 |
| Johnson & Johnson(2 entities) | 158 | $217,093 |
| Janssen Scientific Affairs, LLC | 99 | $125,186 |
| E.r. Squibb & Sons, L.L.C. | 70 | $111,459 |
| Lilly USA, LLC | 32 | $52,380 |
| Pfizer | 88 | $47,426 |
| Takeda Pharmaceuticals U.S.A., Inc. | 73 | $1,190 |
| Bristol Myers Squibb | 30 | $492 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $481 |
| Merck | 7 | $225 |
| Daiichi Sankyo Inc. | 9 | $189 |
| Celltrion USA Inc. | 7 | $168 |
| Ferring Pharmaceuticals Inc. | 8 | $138 |
| Sandoz | 5 | $119 |
| Boston Scientific | 2 | $103 |
| Aimmune Therapeutics, Inc. | 4 | $69 |
| Nestle Healthcare Nutrition Inc. | 3 | $64 |
| Ironwood Pharmaceuticals, Inc | 3 | $55 |
| Sanofi | 2 | $41 |
| Madrigal Pharmaceuticals | 1 | $36 |
| Sanofi-aventis U.S. LLC | 1 | $36 |
| Organon | 2 | $35 |
| Medtronic | 1 | $32 |
| UCB, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Biocon Biologics Inc | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Vivus LLC | 1 | $22 |
| Braintree Laboratories, Inc. | 1 | $21 |
| Mylan Institutional Inc. | 1 | $21 |
| Ardelyx, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Intra-sana Laboratories | 1 | $15 |
| Lumendi LLC | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,071,300 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 245 | $6,689,898 |
| Humira(Cf) PenAdalimumab | 87 | $710,569 |
| Skyrizi On-BodyRisankizumab-Rzaa | 29 | $627,628 |
| RinvoqUpadacitinib | 66 | $566,977 |
| Cimzia (2 Pack)Certolizumab Pegol | 19 | $119,812 |
| CreonLipase/Protease/Amylase | 11 | $41,922 |
| Mesalamine | 49 | $37,325 |
| LinzessLinaclotide | 28 | $31,485 |
| Balsalazide Disodium | 197 | $24,744 |
| Mesalamine ErMesalamine | 57 | $17,266 |
| Pantoprazole Sodium | 407 | $5,943 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 75 | $5,044 |
| Sulfasalazine | 109 | $3,937 |
| Budesonide DrBudesonide | 20 | $3,727 |
| Esomeprazole Magnesium | 31 | $3,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $217,093 | $6,689,898245 claims |
| AbbVieRinvoq, Creon, Linzess | $514,017 | $640,385105 claims |
| UCB, Inc.Cimzia (2 Pack) | $30 | $119,81219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Atlanta
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Roshan ShresthaAtlanta$317K
- Hetal KarsanAtlanta$314K
- Marc SonenshineAtlanta$201K
- Julia LiuAtlanta$163K
- Huiming HonAtlanta$159K
- Norman GitlinAtlanta$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.